Back to today’s briefing

Story perspectives

FDA Rejects Key Psychiatric Treatments Amid Safety Concerns

2/21/2025

37 5

Summary

Story summary

In the past year, the landscape of psychiatric treatments has been rocky. The FDA turned down roluperidone for schizophrenia, citing a lack of robust data. Similarly, navacaprant and emraclidine fell short in trials for major depressive disorder and schizophrenia. Moreover, MDMA-assisted therapy for PTSD was also rejected, necessitating more trials to ensure its safety and effectiveness.

1 of 1

Story summary

In the past year, the landscape of psychiatric treatments has been rocky. The FDA turned down roluperidone for schizophrenia, citing a lack of robust data. Similarly, navacaprant and emraclidine fell short in trials for major depressive disorder and schizophrenia. Moreover, MDMA-assisted therapy for PTSD was also rejected, necessitating more trials to ensure its safety and effectiveness.